2. Signaling Pathways
  3. Immunology/Inflammation
  4. PSMA
  5. PSMA Inhibitor

PSMA Inhibitor

PSMA Inhibitors (23):

Cat. No. Product Name Effect Purity
  • HY-W054292
    tert-Butyl-DCL
    		Inhibitor ≥98.0%
    tert-Butyl-DCL is a small molecule PSMAM inhibitor with anticancer activity that targets prostate-specific membrane antigen (PSMA). tert-Butyl-DCL is also an effective bioimaging agent that has high selectivity and affinity, allowing it to target and highlight specific receptors on the surface of tumor cells.
  • HY-173476
    TcO-ABX474
    		Inhibitor
    TcO-ABX474 (TcO-5) is a potent prostate-specific membrane antigen (PSMA) inhibitor with a Kd value of 6.1 nM. TcO-ABX474 inhibits prostate cancer cell growth and metastasis. TcO-ABX474 is promising for research of prostate cancer.
  • HY-P991360
    MLN 591
    		Inhibitor
    MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research.
  • HY-P99517
    Voxalatamab
    		Inhibitor 99.90%
    Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer.
  • HY-P9992
    Pelgifatamab
    		Inhibitor 99.86%
    Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research.
  • HY-139840A
    GCPII-IN-1 TFA
    		Inhibitor 99.58%
    GCPII-IN-1 (Compound 2) TFA is a GCPII (also known as PSMA) inhibitor scaffold with a Ki of 44.3 nM. GCPII-IN-1 TFA can be used in the research of prostate cancer.
  • HY-139840
    GCPII-IN-1
    		Inhibitor 99.83%
    GCPII-IN-1 (Compound 2) is a GCPII (also known as PSMA) inhibitor scaffold with a Ki of 44.3 nM. GCPII-IN-1 can be used in the research of prostate cancer.
  • HY-158266
    DOTA-PSMA-EB-01
    		Inhibitor
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-163683
    EB-PSMA-617
    		Inhibitor
    EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity.
  • HY-P991204
    Anti-PSMA Antibody
    		Inhibitor
    Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-129615
    MIP-1072
    		Inhibitor
    MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer.
  • HY-123733
    MIP-1095
    		Inhibitor
    MIP-1095 potently inhibits the glutamate carboxypeptidase activity of PSMA (Ki =0.24 nM).
  • HY-P991359
    Anti-FOLH1/PSMA Antibody (J591)
    		Inhibitor
    Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody; ADCT-401 antibody) is a human monoclonal antibody (mAb) targeting PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research.
  • HY-163196
    PSMA-IN-4
    		Inhibitor
    PSMA-IN-4 (compound 9) is a potent inhibitor of PSMA, with the IC50 value of 1.2 μM.
  • HY-149297
    PSMA-IN-1
    		Inhibitor
    PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a Ki value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λEX: 620 nm; λEM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer.
  • HY-162779
    CDD-3290
    		Inhibitor
    CDD-3290 (Compound 20) is a prostate-specific antigen (PSA) inhibitor with a Ki value of 216 nM. CDD-3290 also inhibits α-chymotrypsin and elastase.
  • HY-16215
    Mipsagargin
    		Inhibitor
    Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research.
  • HY-174808
    SC691
    		Inhibitor
    SC691 is a PSMA inhibitor. SC691 can be labeled with 68Ga(III). SC691 can be used for imaging diagnosis of prostate cancer.
  • HY-174440
    BWD
    		Inhibitor
    BWD is a PSMA ligand (IC50 = 35.86). BWD exhibits excellent in vitro stability and high affinity. BWD can enhance tumor uptake and retention. BWD can inhibit tumor growth in vivo. BWD can be studied in anticancer research.
  • HY-149298
    PSMA-IN-2
    		Inhibitor
    PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice.